The alliance will utilize Trubion’s small modular immunopharmaceuticals (SMIPs), a novel class of immunotherapeutics with enhanced drug properties over monoclonal and recombinant antibodies. SMIPs are smaller than antibodies
Aspreva is currently conducting a global phase III study evaluating the efficacy and safety of CellCept in maintaining or improving symptom control with reduced doses of corticosteroids in
The trial is expected to enroll 49 patients with metastatic breast cancer who have relapsed following prior treatment with an anthracycline and taxane regimen. The primary objective of
The new drug application is primarily based on one-year data from the GLOBE study, an ongoing two-year phase III clinical trial comparing telbivudine with a standard therapy, lamivudine,
The payment was in connection with the closing of the deal that was first announced in November 2005. The value of this alliance could eventually exceed $400 million,
Review of the application is coordinated by the European medicines authority (EMEA). The procedure affords for a centralized authorization that is valid in all 25 member states of
Multicell will rename the compound to MCT-125, and will further evaluate it in a pivotal phase IIb/III clinical trial, which is expected to begin before the end of
The results, published in Mayo Clinic Proceedings, are the result of the largest US study to date of the treatment of restless legs syndrome (RLS). Requip is the
Preclinical studies demonstrate the potential of CRS-100 to stimulate a potent immune response against certain cancers in the liver. Cerus hopes to initiate a phase I clinical trial
The drug is currently approved for the treatment of acute manic episodes associated with bipolar disorder and the treatment of schizophrenia. Bipolar disorder consists of recurring episodes of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.